Table 3.
Influencing parameters for outcome, incremental cost and incremental cost effectiveness ratio (ICER) in the models
| Parameters | Outcomes | Incremental costs | ICER | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DALY averted | QALY gained | Per DALY averted | Per QALY gained | |||||||||
| TriVac (default) | TriVac (± 20%) | ADIP (± 20%) | SUPR (± 20%) | TriVac (default) | TriVac (± 20%) | ADIP (± 20%) | SUPR (± 20%) | TriVac (default) | TriVac (± 20%) | ADIP (± 20%) | SUPR (± 20%) | |
| Population: | ||||||||||||
| Total number of births per year | + | + | ++ | 0 | + | + | +++ | ++++ | + | + | ++ | |
| Life expectancy at birth | 0 | + | ++ | ++ | 0 | 0 | + | 0 | 0 | + | ++ | |
| Under 5 years mortality per 1,000 live births | 0 | ++ | - | - | 0 | + | - | - | 0 | ++ | - | |
| Burden of disease: | ||||||||||||
| Incidence of pneumococcal pneumonia (per 100,000 per year) | ++ | ++ | ++ | - | + | + | ++++ | - | ++ | ++ | - | |
| Incidence of meningitis (per 100,000 per year) | ++ | + | + | - | + | + | + | - | ++ | + | - | |
| Incidence of invasive NPNM (per 100,000 per year) | ++ | ++ | + | - | + | + | + | - | ++ | ++ | - | |
| Prevalence of bacteremia sp < 10 years (cases per year) | - | - | - | ++ | - | - | - | + | - | - | ++ | |
| Case fatality rate of pneumococcal pneumonia | 0 | ++ | ++ | + | 0 | 0 | + | 0 | 0 | ++ | + | |
| Case fatality rate of invasive NPNM | 0 | ++ | + | ++ | 0 | 0 | + | 0 | 0 | ++ | ++ | |
| Vaccine information: | ||||||||||||
| Vaccine efficacy of pneumococcal pneumonia | ++ | ++ | ++ | ++ | + | + | + | + | ++ | ++ | ++ | |
| Vaccine efficacy of pneumococcal invasive NPNM | + | ++ | + | ++ | + | + | + | + | + | ++ | ++ | |
| Vaccine efficacy adjusted NTHi | - | - | - | ++ | - | - | - | + | - | - | ++ | |
| Vaccine coverage | + | + | ++ | ++ | + | ++ | ++++ | +++ | + | + | ++ | |
| Serotype coverage of pneumococcal pneumonia | +++ | ++ | ++ | + | + | + | ++++ | + | +++ | ++ | ++ | |
| Number of doses | - | - | - | + | - | - | - | +++ | - | - | +++ | |
| Dose cost | 0 | 0 | 0 | 0 | 0 | +++ | ++ | +++ | 0 | ++ | ++ | |
| Other parameters: | ||||||||||||
| Coverage 20 years after vaccine introduced (dose 1) | + | ++ | - | - | + | ++ | - | - | + | ++ | - | |
| Coverage 20 years after vaccine introduced (dose 3) | + | ++ | - | - | + | ++ | - | - | + | ++ | - | |
| GP visits < 10 years (AOM) | - | - | - | ++ | - | - | - | + | - | - | ++ | |
| Proportion sp of AOM | - | - | - | ++ | ||||||||
| Probability of death | - | - | - | ++ | - | - | - | 0 | - | - | ++ | |
0 = no change; - = not available; + = percentage change < 5%; ++ = percentage change 5% to 30%; +++ = percentage change 30% to 50%; ++++ = percentage change > 50%.
AOM = acute otitis media; NPNM = non-pneumonia non-meningitis; NTHi = non-typeable Haemophilus influenza.
ADIP = Pneumo ADIP; SUPR = Supremes